When glomerular function was measured at day 14, FSGS mice treated with the control antibody had proteinuria in the nephrotic range, which was significantly lowered by the anti–PD-1 treatment (Figure 11G). Here, PDCD1 is linked to focal segmental glomerulosclerosis.